EC pledges €4.9bn to grant access to medicines
Under the Coronavirus Global Response Framework, the European Commission is allocating further €4.9bn to assure access to COVID-19 countermeasures for poor countries.
ADVERTISEMENT
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 2080 entries already.
Entries by Thomas Gabrielczyk
An Outline of the German Medical Cannabis Market
The medical cannabis market has grown significantly in recent years. In Germany, the quantity of imported cannabis products has increased dramatically. In comparison to only 1.2 tons in 2017, German medical cannabis distributors imported about 3.13 metric tons of cannabis flowers for direct medical care of patients in 2018, while around 120 kg have been re-exported. In 2019, this amount doubled to around 6.7 tons.
BioGeneration Ventures closes BGV IV Fund at €105m
BioGeneration Ventures has closed its fourth VC fund for European start-ups (BGV IV) at €105m.
LSP leads €11m Series A round in OneProject
OneProjects Ltd, an Irish-German cardiac imaging specialist, has closed an €11m Series A financing led by Amsterdam-headquartered life sciences investor LSP.
Illumina and Epidarex Capital invest in post-Brexit UK
Illumina has opened its first accelerator outside the US in Cambridge to fund genomics start-ups. Meanwhile, Epidarex Capital has raised £102m for UK biotechs.
Novel adjuvant teases T cells to respond to HCV
Researchers from Italy, Denmark and the UK have devised a new vaccination strategy to tackle hepatitis C and boosting the required strong T cell response.
First drug found to reduce COVID-19-mortality
A clinical trial has identified the first immuno-modulatory drug to significantly reduce COVID-19 mortality in ventilated patients.
Germany puts €300m in CureVac AG for COVID-19 vaccine
In the race aimed at securing access to COVID-19 vaccines, Germany has acquired a minority stake in the local mRNA vaccine producer Curevac AG.
Antimicrobial resistance This is not the time to wait. This is the time to act.
Emperor Nero, reportedly, fiddled as Rome burned in 64 A.D., much like society for a long time ignored and repressed the pending crisis of antimicrobial resistance (AMR).
Abbvie and Genmab team up in oncology
AbbVie is partnering with Genmab A/S to commercialise up to seven new antibody formats.